Literature DB >> 18552537

[Arthroplasty for the treatment of joint degeneration caused by ochronosis in two cases].

Mehmet Kefeli1, Yilmaz Tomak, Bilge Can, Sancar Bariş.   

Abstract

Ochronosis is a rare metabolic disease caused by the deficiency of the homogentisic acid oxidase enzyme. With increasing age, accumulation of pigment deposits of homogentisic acid in the joint cartilage results in ochronotic osteoarthritis. We presented two female patients, with ages 55 and 60 years, who underwent staged bilateral uncemented total hip and bilateral cemented total knee arthroplasty, respectively, for osteoarthritis caused by ochronosis. Both patients had no significant complaints at final follow-up examinations made 12 months and 10 months after the second operation in the hip and knee, respectively. Plain radiographs did not show any abnormality in the components of the prostheses. Histopathologic examination of surgical specimens showed brown-black pigment deposits in the connective tissue and cartilage tissue.

Entities:  

Mesh:

Year:  2008        PMID: 18552537     DOI: 10.3944/aott.2008.42.2.139

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  3 in total

1.  Clinical and radiological outcomes of total joint arthroplasty in patients with ochronotic arthropathy.

Authors:  Natesan Rajkumar; Dhanasekaran Soundarrajan; Palanisami Dhanasekararaja; Shanmuganathan Rajasekaran
Journal:  Eur J Orthop Surg Traumatol       Date:  2020-03-14

2.  Long-term result of arthroplasty in the treatment of a case of ochronotic arthropathy.

Authors:  Sinan Karaoğlu; Fatih Karaaslan; Musa Uğur Mermerkaya
Journal:  Acta Orthop Traumatol Turc       Date:  2016-11-03       Impact factor: 1.511

3.  Ochronotic arthritis and ochronotic Achilles tendon rupture in alkaptonuria: A 6 years follow-up case report in China.

Authors:  Lifeng Jiang; Le Cao; Jinghua Fang; Xinning Yu; Xuesong Dai; Xudong Miao
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.